ReviewAdvances in experimental medicine and biology2026
Blood-Based Metabolomic Biomarkers and Personality Traits in Major Depressive Disorder: Toward an Integrated Framework for Precision Psychiatry.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a heterogeneous condition influenced by biological, psychological, and cultural factors. Recent blood-based metabolomic studies have identified alterations in pathways such as the tricarboxylic acid cycle, γ-aminobutyric acid, and the tryptophan-kynurenine axis, which are associated with depressive states, suicidality, and treatment response. In parallel, personality traits-particularly high neuroticism and low extraversion-have been shown to shape vulnerability, symptom presentation, and therapeutic outcomes. Combining personality assessment with metabolomic profiling enhances diagnostic accuracy and allows the identification of biologically distinct subtypes, separating personality-driven from personality-neutral depression. These advances hold clinical potential for improving diagnostic support, stratifying suicide risk, and tailoring individualized treatment strategies. Advancing this field will require longitudinal and multi-omics studies that incorporate digital and behavioral markers, enhanced through artificial intelligence. The aim of this review is to highlight how linking biomarkers with personality traits can foster the development of precision psychiatry, ultimately paving the way for more personalized and culturally sensitive care in depression.
Indexed as
Identifiers
42036559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.